Eli Lilly and Company (NYSE:LLY) Shares Bought by Platform Technology Partners

Platform Technology Partners increased its position in Eli Lilly and Company (NYSE:LLY) by 2.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,088 shares of the company’s stock after buying an additional 45 shares during the quarter. Platform Technology Partners’ holdings in Eli Lilly and Company were worth $917,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. Ignite Planners LLC raised its position in Eli Lilly and Company by 75.6% during the second quarter. Ignite Planners LLC now owns 2,023 shares of the company’s stock valued at $915,000 after buying an additional 871 shares during the period. MJP Associates Inc. ADV raised its position in Eli Lilly and Company by 37.3% during the second quarter. MJP Associates Inc. ADV now owns 2,215 shares of the company’s stock valued at $1,039,000 after buying an additional 602 shares during the period. WJ Wealth Management LLC acquired a new position in Eli Lilly and Company during the second quarter valued at $375,000. Pioneer Trust Bank N A OR acquired a new position in Eli Lilly and Company during the second quarter valued at $1,304,000. Finally, Occidental Asset Management LLC increased its position in Eli Lilly and Company by 15.8% in the 2nd quarter. Occidental Asset Management LLC now owns 1,833 shares of the company’s stock worth $860,000 after purchasing an additional 250 shares during the last quarter. 81.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total value of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 107,022 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the completion of the sale, the insider now owns 101,248,810 shares in the company, valued at $46,501,553,456.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total value of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,010,309 shares of company stock valued at $21,095,701,670. 0.13% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their target price for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. Credit Suisse Group upped their price target on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. UBS Group increased their target price on Eli Lilly and Company from $447.00 to $498.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. Truist Financial increased their target price on Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, StockNews.com assumed coverage on Eli Lilly and Company in a research note on Thursday, August 17th. They set a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Trading Down 0.4 %

LLY stock traded down $2.27 during midday trading on Monday, hitting $573.39. 1,406,820 shares of the company’s stock were exchanged, compared to its average volume of 3,029,935. The stock’s fifty day moving average price is $512.56 and its 200-day moving average price is $439.28. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The company has a market cap of $544.31 billion, a PE ratio of 79.56, a price-to-earnings-growth ratio of 2.44 and a beta of 0.32. Eli Lilly and Company has a one year low of $296.32 and a one year high of $601.84.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same quarter last year, the business posted $1.25 EPS. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 62.87%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.